|
Apr 18
|
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
|
|
Apr 15
|
Bio-Path Holdings Expands Global Patent Portfolio
|
|
Apr 2
|
Bio-Path Holdings Provides 2024 Clinical and Operational Update
|
|
Mar 27
|
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
|
|
Mar 10
|
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
|
|
Mar 9
|
Q4 2023 Bio Path Holdings Inc Earnings Call
|
|
Mar 8
|
Bio-Path Holdings Reports Full Year 2023 Financial Results
|
|
Feb 17
|
When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
|
|
Jan 10
|
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
|
|
Nov 15
|
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
|
|
Nov 8
|
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
|